OncLive.com路 @OncLive 路 X路路 2 days agoScore45
Body 路 original
馃К What could a CLDN18.2-directed ADC offer patients with previously treated advanced gastric cancer?
At @esmoESMO #ESMO26, phase 3 G-HOPE-001 results highlight the potential of arcotatug tavatecan.
Read more: https://www.onclive.com/view/arcotatug-tavatecan-improves-survival-in-cldn18-2-advanced-gastric-or-gej-adenocarcinoma #oncology
278 views 路 0 likes 路 0 reposts 路 0 replies
Conference abstracts
LBA77matched by Proffered paper 1: Gastrointestinal tumour, upper digestive
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician鈥檚 choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.orgSource: OncLive.com 路 x.com